Urology Times | LinkedIn (original) (raw)
About us
Urology Times takes the lead in providing news analysis of key advances in surgical and non-surgical techniques, treatments, and practice management. Urology Times has been the #1 read publication for more than 20 years, reaching the full universe of physician-specialists treating urologic disorders. We keep urologists up to date so they can quickly provide better patient care while running a more efficient practice.
Industry
Book and Periodical Publishing
Company size
51-200 employees
Type
Public Company
Specialties
Urology
Employees at Urology Times
Updates
-
5,020 followers
23h Edited
Findings from a real-world study of UGN-101 showed that the therapy led to a 3-year recurrence-free survival rate of 68% among patients with low-grade #UTUC. Data also showed a reduced risk of recurrence among those who received maintenance therapy. According to the authors, further research is needed to clarify the role of maintenance therapy and assess durability and potential late adverse events. Learn more here: https://lnkd.in/gspZtVFT UT Southwestern Medical Center - Our upcoming expert-led presentation will provide an in-depth discussion the importance of shared decision making for optimal patient care. Don’t miss our live upcoming broadcast to listen to Yair Lotan, MD, Brooke Zilinskas, MMS, PA-C, and Robert Svatek, MD, MSCJ discuss the patient journey and unmet treatment needs in Non-muscle Invasive Bladder Cancer (NMIBC). Register now https://bit.ly/3WcRQqV
-
5,020 followers
1d Edited
Max Kates, MD, discusses the evolving landscape of treating BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). Watch now to gain valuable clinical and operational perspectives. Watch the video: https://bit.ly/42hTLyp -
5,020 followers
2d Edited
Findings from the BladderPath trial suggest that adding mpMRI into the initial staging pathway for patients with MIBC can expedite the time to definitive treatment. Specifically, data showed that the median time to correct treatment was 98 days when patients underwent initial TURBT vs 53 days when they underwent initial mpMRI. According to the authors, this quicker time to treatment was achieved without detriment to participants with #NMIBC. Learn more and hear from Prof. Rik Bryan, of the University of Birmingham: https://lnkd.in/eibwCi7r #BLCSM - The combination of belzutifan and cabozantinib elicited durable responses with manageable toxicities in treatment-naive patients with ccRCC, according to data from the phase 2 LITESPARK-003 trial. At a median follow-up of 24.3 months, the confirmed objective response rate was 70%. Read more on the findings here: https://lnkd.in/eJGDnkhu Toni Choueiri | Dana-Farber Cancer Institute #KCSM
- Our upcoming expert-led presentation will provide an in-depth discussion the importance of shared decision making for optimal patient care. Don’t miss our live upcoming broadcast to listen to Yair Lotan, MD, Brooke Zilinskas, MMS, PA-C, and Robert Svatek, MD, MSCJ discuss the patient journey and unmet treatment needs in Non-muscle Invasive Bladder Cancer (NMIBC). Register now https://bit.ly/3WcRQqV